Where Will Gossamer Bio Inc (GOSS) Stock Go Next After It Has Fallen 4.76% in a Week?

Gossamer Bio Inc (GOSS) stock is lower by 4.76% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Gossamer Bio Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on GOSS!

See Full GOSS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With GOSS Stock Today?

Gossamer Bio Inc (GOSS) stock is unchanged 0.34% while the S&P 500 is up 0.53% as of 1:20 PM on Monday, Sep 11. GOSS is unmoved $0.00 from the previous closing price of $0.99 on volume of 645,663 shares. Over the past year the S&P 500 is up 9.02% while GOSS has fallen -92.85%. GOSS lost -$2.21 per share in the over the last 12 months. To screen for more stocks like Gossamer Bio Inc click here.

More About Gossamer Bio Inc

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. Click Here to get the full Stock Report for Gossamer Bio Inc stock.